Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

L-5-Hydroxytryptophan (L-5-HTP; Oxitriptan)

  Cat. No.:  DC20041   Featured
Chemical Structure
4350-09-8
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist. L-5-Hydr
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 4350-09-8
Chemical Name: 5-Hydroxy L-Tryptophan
Synonyms: 5-Hydroxy-L-tryptophan;2-AMINO-3-(5-HYDROXY-1H-INDOL-3-YL)PROPIONIC ACID;5-HTP;5-HYDROXY-L-TRP-OH;(-)-5-HYDROXY-L-TRYPTOPHAN;5-HYDROXY-TRP-OH;5-HYDROXYTRYPTOPHAN;C5-HYDROXY-L-TRYPTOPHAN;H-5-HYDROXY-TRP-OH;H-TRP(5-OH)-OH;L-2-AMINO-3-(5-HYDROXYINDOLYL)PROPIONIC ACID;L-5-HTP;L-5-HYDROXYTRYPTOPHAN;L-5-HYDROXYTRYPTOPHAN HYDRATE;OXITRIPTAN;(S)-2-AMINO-3-(5-HYDROXY-1H-INDOL-3-YL)-PROPIONIC ACID;5-hydroxy-l-tryptopha;5-Hydroxy-L-tryptophan, Free Acid;Griffonia seed;5-Hydroxy L-Tryptophan;5-Hydroxy-L-tryptophane;(2S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid;L-5-HTP L-2-Amino-3-(5-hydroxyindolyl)propionic acid;[ "L-5-HTP" ];Levothym;Cincofarm;Tryptophan, 5-hydroxy-;Pretonine;Tript-OH;Quietim;5-Hydroxytryptophan L-form;Oxyfan;Telesol;Serotonyl;5-Hydroxyl-L-tryptophan;(S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid;L-Tryptophan, 5-hydroxy-;Oxitriptan [INN];Oxitriptanum [INN-Latin];Oxitriptano [INN-Spanish];Tryptophan, 5-hydrox;Tryptophan, 5-hydr;pretonine;L-2-Amino-3-(5-hydroxyindolyl)propionic acid;H-Trp(5-OH)-OH;Oxitriptan;MFCD00064341;A826297;HYDROXYTRYPTOPHAN [VANDF];Tryptophan, 5-hydroxy-, dl;Lopac-H-9772;L-oxitriptan;NCGC00091062-09;5-hydroxytryptophan, dl-;EN300-1720935;BRN 0088200;OXITRIPTAN [WHO-DD];Oxitriptano (INN-Spanish);OXITRIPTAN (MART.);DTXCID005437;Tripten;4350-09-8;MLS002153452;Q-200544;Triptene;HMS3261N16;5-HYDROXYTRYPTOPHAN L-FORM [MI];5-Hydroxytryptophan L form;2S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoicacid;Z2044741046;5-hydroxytryptophan;CHEMBL350221;AM20060629;SDCCGSBI-0050608.P002;bmse000457;SMR001230815;AS-12269;HYDROXYTRYPTOPHAN [INCI];L-5-Hydroxytryptophan;Levothym (TN);C00643;5-hydroxy-L-tryptophane;UNII-C1LJO185Q9;5-hydroxy tryptophan;4PQ;5-HTP Phenolic;CCRIS 4418;Ro 3-5940 HCl;NS00002848;Tox21_500627;L-5-Htp;OXITRIPTAN [MART.];TRYPTOPHAN IMPURITY D [EP IMPURITY];NCGC00091062-12;Tox21_111073;Lopac0_000627;NCGC00091062-08;EINECS 224-411-1;5-22-14-00278 (Beilstein Handbook Reference);(S)-5-Hydroxytryptophan;Tox21_111073_1;GTPL4671;NCGC00258585-01;CS-W019879;BDBM50403163;Dl-oxitriptan;NCGC00091062-07;5-hydroxy-L-tryptophan;L-5-Hydroxytryptophan (L-5-HTP; Oxitriptan);s4769;5-HYDROXY-TRYPTOPHAN;NCGC00091062-01;oxitriptan;5-Hydroxytryptophane;HMS2231H15;(S)-2-Amino-3-(5-hydroxy-1H-indol-3-yl)propanoic Acid (5-Hydroxytryptophan);H0531;D07339;Oxitriptanum (INN-Latin);N-ACETYLTRYPTOPHAN IMPURITY D [EP IMPURITY];NCGC00091062-05;H 9772;SR-01000075584-1;DTXSID1025437;NCGC00091062-03;Oxitriptan (INN);CHEBI:17780;Levotinine;C1LJO185Q9;LP00627;5-Hydroxy-L-tryptophan, United States Pharmacopeia (USP) Reference Standard;NCGC00261312-01;HY-B1716;CAS-4350-09-8;(2S)-2-amino-3-(5-hydroxyindol-3-yl)propanoic acid;(2S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoicacid;CCG-204715;AKOS004119863;NCGC00091062-02;hydroxytryptophan;5-HYDROXY-L-TRYPTOPHAN [USP-RS];SR-01000075584;NCGC00015526-01;CDAD59D9-D915-46DD-8029...
SMILES: O([H])C1C([H])=C([H])C2=C(C=1[H])C(=C([H])N2[H])C([H])([H])[C@@]([H])(C(=O)O[H])N([H])[H]
Formula: C11H12N2O3
M.Wt: 220.2246
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868 AZ14133346 AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865 TI17 ​​TI17​​ represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816 Nisoxetine Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641 GENZ-644282 TFA salt Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325 PSMA-617 TFA PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202 Fosaprepitant free acid Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748 O4I4 O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684 ZH8667 ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646 EB-PSMA-617 EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia